[go: up one dir, main page]

BRPI0818673A2 - terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2 - Google Patents

terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2

Info

Publication number
BRPI0818673A2
BRPI0818673A2 BRPI0818673A BRPI0818673A BRPI0818673A2 BR PI0818673 A2 BRPI0818673 A2 BR PI0818673A2 BR PI0818673 A BRPI0818673 A BR PI0818673A BR PI0818673 A BRPI0818673 A BR PI0818673A BR PI0818673 A2 BRPI0818673 A2 BR PI0818673A2
Authority
BR
Brazil
Prior art keywords
bcl
antibody
type
active agent
combination therapy
Prior art date
Application number
BRPI0818673A
Other languages
English (en)
Inventor
Christian Klein
Pablo Umana
Pamela Braemer
Thomas Friess
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38904707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818673(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BRPI0818673A2 publication Critical patent/BRPI0818673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0818673A 2007-10-15 2008-10-13 terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2 BRPI0818673A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07020120 2007-10-15
PCT/EP2008/008635 WO2009049841A1 (en) 2007-10-15 2008-10-13 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent

Publications (1)

Publication Number Publication Date
BRPI0818673A2 true BRPI0818673A2 (pt) 2015-09-08

Family

ID=38904707

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818673A BRPI0818673A2 (pt) 2007-10-15 2008-10-13 terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2

Country Status (16)

Country Link
US (6) US20090098118A1 (pt)
EP (2) EP2203185A1 (pt)
JP (1) JP5416124B2 (pt)
KR (1) KR101278395B1 (pt)
CN (1) CN101827611B (pt)
AR (1) AR068862A1 (pt)
AU (1) AU2008314068B2 (pt)
BR (1) BRPI0818673A2 (pt)
CA (1) CA2702300A1 (pt)
CL (1) CL2008003035A1 (pt)
IL (1) IL204744A0 (pt)
MX (1) MX2010003815A (pt)
PE (1) PE20090966A1 (pt)
RU (1) RU2541805C2 (pt)
TW (1) TWI430809B (pt)
WO (1) WO2009049841A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101364902B1 (ko) * 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
WO2008144506A1 (en) * 2007-05-16 2008-11-27 University Of Maryland, Baltimore Apoptotic pathway targeting for the diagnosis and treatment of cancer
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101920202B1 (ko) * 2009-05-26 2018-11-21 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20130203709A1 (en) * 2010-08-09 2013-08-08 The Penn State Research Foundation Acylsulfonamides and processes for producing the same
JP5841149B2 (ja) 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー 抗テネイシンｃａ２抗体及び使用の方法
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
EP2651976A1 (en) * 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
KR101274731B1 (ko) * 2011-01-18 2013-06-18 동아대학교 산학협력단 레스베라트롤의 유사체인 ｈｓ－１７９３ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 하는 전립선 암 치료용 약학적 조성물
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN102222176A (zh) * 2011-06-01 2011-10-19 山东大学 一种快速发现以Bcl-2蛋白为靶点的先导化合物的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
BR112017023517A2 (pt) * 2015-05-26 2018-07-24 F. Hoffmann-La Roche Ag anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3658584A1 (en) * 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019315466B2 (en) * 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114269371A (zh) 2019-06-12 2022-04-01 朱诺治疗学股份有限公司 细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230173094A1 (en) * 2020-04-27 2023-06-08 Aruna Bio, Inc. Binding agents and uses thereof for central nervous system delivery
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US371191A (en) 1887-10-11 Cloth-sponging machine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT1584682E (pt) 1993-09-20 2009-08-03 Univ Pennsylvania Regulação da expressão do gene bcl-2
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
SI1558648T1 (sl) 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004056971A2 (en) 2002-12-19 2004-07-08 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
NZ591970A (en) 2003-01-22 2012-11-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
KR101168441B1 (ko) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법
EP1844815B1 (en) * 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
KR101364902B1 (ko) * 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
EP1732529A4 (en) * 2004-03-25 2009-02-25 Univ Michigan GOSSYPOL KOKRISTALLE AND ITS USE
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHOD FOR TREATING ARTHRITIS WITH TRIHETEROCYCLIC COMPOUNDS
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
NZ561609A (en) * 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
JP5373396B2 (ja) 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子

Also Published As

Publication number Publication date
EP2604277A1 (en) 2013-06-19
JP2011500521A (ja) 2011-01-06
CL2008003035A1 (es) 2010-01-11
TW200920401A (en) 2009-05-16
RU2010118448A (ru) 2012-05-20
MX2010003815A (es) 2010-08-04
JP5416124B2 (ja) 2014-02-12
CA2702300A1 (en) 2009-04-23
IL204744A0 (en) 2010-11-30
CN101827611B (zh) 2014-01-15
US20120276085A1 (en) 2012-11-01
KR101278395B1 (ko) 2013-06-24
TWI430809B (zh) 2014-03-21
PE20090966A1 (es) 2009-07-13
EP2203185A1 (en) 2010-07-07
AU2008314068A1 (en) 2009-04-23
WO2009049841A1 (en) 2009-04-23
AU2008314068B2 (en) 2014-01-16
US20110086025A1 (en) 2011-04-14
US20110287006A1 (en) 2011-11-24
RU2541805C2 (ru) 2015-02-20
US20090098118A1 (en) 2009-04-16
CN101827611A (zh) 2010-09-08
US20150056186A1 (en) 2015-02-26
AR068862A1 (es) 2009-12-09
KR20100056559A (ko) 2010-05-27
US20140004104A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
CY2020043I1 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
LTPA2018006I1 (lt) Pakeistųjų oksazolidinonų kombinuota terapija
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
PL3150586T3 (pl) Modulatory farmakokinetycznych właściwości środków terapeutycznych
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
ME01814B (me) Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena
HUE069458T2 (hu) Terápiás hatóanyagok bejuttatására szolgáló új lipidek és készítmények
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
PL15177166T1 (pl) Modulatory receptora s1p do leczenia stwardnienia rozsianego
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0821145A2 (pt) Agente terapêutico para prurido
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
DK2144905T3 (da) Terapeutiske midler
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
DK2222315T3 (da) Stabiliserede faktor-ix-formuleringer indeholdende trehalose
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0716118A2 (pt) agente anti-ruga
BRPI0817974A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas.
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
BRPI0815726A2 (pt) terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico
BRPI0910912A2 (pt) Composto, prodroga, ativador de glicocinase, agente farmacêutico, e, uso do composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.